PARK-BAND training program for Parkinson’s disease in clinical settings: A feasibility study.
Objective: To describe indicators of feasibility, including acceptability and safety, of Power training (PT) in Parkinson’s Disease (PD). Background: PT is a specific method of…Reversible MIBG Abnormalities in Subjects at Risk for Synucleinopathy: 12 months data
Objective: To investigate the long-term effects of the adrenergic blocker carvedilol on I-MIBG myocardial uptake in subjects with REM sleep behavior disorder (RBD) and other…Efficacy of a 6-week brisk walking program in improving non-motor symptoms in people with Parkinson disease – a randomized controlled trial
Objective: To examine whether the brisk walking program would be effective in alleviating non-motor symptoms, and improving sleep quality and health-related quality-of-life (HRQoL) in people…The Role of the PD Diary Trainer/Reviewer in Parkinson’s Disease Clinical Trials
Objective: To examine the experience profile of PD Diary raters in clinical trials Background: The Parkinson’s Disease (PD) Home Diary (Hauser, 2000)1 is a widely…The Hauser Diary knowledge test as a tool to improve Rater Training Programs in Parkinson’s disease clinical trials
Objective: To identify the areas with specific training needs for Rater Training Programs (RTP) on the Hauser Diary in Parkinson’s disease (PD) clinical trials Background:…Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease
Objective: To describe blindness for treatment allocation in STEADY-PD3 and understand the reasons for perceived treatment allocation. Background: The use of a placebo arm aims…Decreased expression of trace amines receptors on lymphocytes in Parkinson’s disease
Objective: To determine the expression of TAAR1 and TAAR2 mRNA in leukocytes of patients with Parkinson's disease, depending on the stage of the disease and…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors
Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease
Objective: Report outcomes from Part 2 of the phase 2 MOVES-PD trial (NCT02906020) in patients with PD stratified by glucocerebrosidase (GBA) gene mutation severity. Background:…
- « Previous Page
- 1
- …
- 736
- 737
- 738
- 739
- 740
- …
- 1734
- Next Page »